Literature DB >> 20167539

Brief dexamethasone treatment during acute infection prevents virus-induced autoimmune diabetes.

Pilar Londono1, Akiko Komura, Naoko Hara, Danny Zipris.   

Abstract

We used the LEW1.WR1 rat to test the hypothesis that Kilham rat virus-induced innate immune activation is involved in the mechanism of autoimmune diabetes. Animals were treated with dexamethasone, an anti-inflammatory glucocorticoid, beginning on the day of infection. Administering dexamethasone on five consecutive days completely blocked the disease. Strikingly, a single dose of dexamethasone was sufficient to prevent islet destruction. Dexamethasone downmodulated inflammation and restored normal ratios between CD8(+) and CD4(+)CD25(+)Foxp3(+) cells in the spleen. Finally, dexamethasone therapy lowered the frequency of splenic anti-virus CD8(+) T cells, but did not interfere with the ability of the host to generate anti-KRV antibodies and eliminate the virus from the spleen. Our data demonstrate a strong association between early virus-induced proinflammatory responses and islet destruction and raise the possibility that targeting innate immune pathways in the early stages of diabetes may be a useful strategy for disease prevention. Copyright 2008 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20167539     DOI: 10.1016/j.clim.2010.01.007

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  17 in total

Review 1.  Targeting Innate Immunity for Type 1 Diabetes Prevention.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2017-09-27       Impact factor: 4.810

2.  Dysregulated Toll-like receptor-induced interleukin-1β and interleukin-6 responses in subjects at risk for the development of type 1 diabetes.

Authors:  Aimon K Alkanani; Marian Rewers; Fran Dong; Kathleen Waugh; Peter A Gottlieb; Danny Zipris
Journal:  Diabetes       Date:  2012-06-29       Impact factor: 9.461

3.  α1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes.

Authors:  Peter A Gottlieb; Aimon K Alkanani; Aaron W Michels; Eli C Lewis; Leland Shapiro; Charles A Dinarello; Danny Zipris
Journal:  J Clin Endocrinol Metab       Date:  2014-02-14       Impact factor: 5.958

Review 4.  The Role of the Intestinal Microbiome in Type 1 Diabetes Pathogenesis.

Authors:  James C Needell; Danny Zipris
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

5.  A lethal disease model for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with Sin Nombre virus.

Authors:  Rebecca L Brocato; Christopher D Hammerbeck; Todd M Bell; Jay B Wells; Laurie A Queen; Jay W Hooper
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

6.  Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes.

Authors:  Naoko Hara; Aimon K Alkanani; Charles A Dinarello; Danny Zipris
Journal:  J Mol Med (Berl)       Date:  2013-08-28       Impact factor: 4.599

Review 7.  Visceral Adipose Tissue: A New Target Organ in Virus-Induced Type 1 Diabetes.

Authors:  Danny Zipris
Journal:  Front Immunol       Date:  2021-08-04       Impact factor: 7.561

8.  Paradigm shift or shifting paradigm for type 1 diabetes.

Authors:  Maki Nakayama; George S Eisenbarth
Journal:  Diabetes       Date:  2012-05       Impact factor: 9.461

9.  Stepwise or linear decrease in penetrance of type 1 diabetes with lower-risk HLA genotypes over the past 40 years.

Authors:  Andrea K Steck; Taylor K Armstrong; Sunanda R Babu; George S Eisenbarth
Journal:  Diabetes       Date:  2011-02-09       Impact factor: 9.461

10.  Testing agents for prevention or reversal of type 1 diabetes in rodents.

Authors:  Christian W Grant; Catherine M Moran-Paul; Shane K Duclos; Dennis L Guberski; Guillermo Arreaza-Rubín; Lisa M Spain
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.